Introduction {#s1}
============

*Staphylococcus aureus* is a leading cause of healthcare-associated infections (HAIs) [@pone.0071055-Hidron1], [@pone.0071055-Blot1]. *S. aureus* infections can cause severe sepsis complicated by acute renal failure and respiratory failure requiring intensive care [@pone.0071055-Burton1], [@pone.0071055-Eber1]. *S. aureus* bacteremia is associated with an in-hospital mortality of as high as 15--60% [@pone.0071055-Lodise1], especially in critically ill patients [@pone.0071055-Cluff1]--[@pone.0071055-Cosgrove1]. Bacteremia of methicillin-resistant *S. aureus* (MRSA) [@pone.0071055-Klevens1]--[@pone.0071055-Hsueh1] has a higher attributable mortality than that of methicillin-susceptible *S. aureus* (MSSA) [@pone.0071055-Blot1], [@pone.0071055-Whitby1]. Thus, *S. aureus* HAIs can have substantial impacts on the patient's survival and well-being.

The negative effects of *S. aureus* HAIs on the outcomes of hospitalized patients have not yet been well studied. The existing literature includes only six small studies, which reported an increased risk for short-term mortality by 2.2--7.3 folds in patients with *S. aureus* HAIs compared to inpatients without HAIs [@pone.0071055-Anderson1]--[@pone.0071055-Chaix1]. Most studies focused on surgical site infection (sample size: 18--286 cases) [@pone.0071055-Anderson1]--[@pone.0071055-McGarry1] or bloodstream infection (sample size: 19 cases) [@pone.0071055-Engemann1]; only one study examined all-type *S. aureus* HAIs (sample size: 27 cases) [@pone.0071055-Abramson1]. None of the studies have investigated the impact of *S. aureus* HAIs on mortality beyond 90 days [@pone.0071055-Leibovici1]. The functional status of survivors has not been studied, either. The acute respiratory or renal failure occurring during sepsis may be irreversible and thus result in long-term ventilator or dialysis dependence, causing huge financial burdens.

Taiwan Nosocomial Infection Surveillance (TNIS) is a nationwide surveillance system that collects HAI data from more than 100 participating hospitals throughout Taiwan. The TNIS data show that *S. aureus* is one of the leading causative pathogens of HAIs in Taiwan [@pone.0071055-Centers1]. MRSA accounts for up to 79% and 81% of all *S. aureus* isolates at regional hospitals and medical centers, respectively [@pone.0071055-Centers1]. To understand the impact of *S. aureus* HAIs on the long-term outcomes of hospitalized patients, we conducted a nationwide population-based matched cohort study of inpatients at 114 hospitals participating in the TNIS.

Methods {#s2}
=======

Study Design {#s2a}
------------

We conducted a retrospective population-based matched cohort study comparing outcomes between hospitalized patients with *S. aureus* HAIs and patients without HAIs, matched by age, gender, hospital, specialty, underlying diseases, and the length of stay before onset of the *S. aureus* HAI. The main outcomes were one-year excess risks for mortality, new-onset chronic ventilator dependence, and new-onset dialysis-dependent end-stage renal disease.

Ethical Statement {#s2b}
-----------------

To protect the privacy of the patients, the personal identification numbers were encrypted before database linking. The study protocol (no. TwCDCIRB990008) was reviewed and approved a priori by the institutional review board (IRB) of Taiwan Centers for Diseases Control (Taipei, Taiwan). The IRB approved the exemption of informed consent because all personal information had been anonymized.

Settings {#s2c}
--------

Taiwan Centers for Diseases Control established the TNIS in 2006 and invited all hospitals to voluntarily participate. By 2008, 114 out of the total 495 hospitals in Taiwan had joined the TNIS and notified their HAIs cases with registration of the patients' personal identification (ID) numbers. The 114 hospitals included 8 medical centers, 43 regional hospitals, and 63 local hospitals (with a median bed capacity of 1318, 581, and 182, respectively), which had a total of 3307878 hospitalizations covered by the NHI during the study period from 2006 through 2008.

HAI Surveillance and Notification {#s2d}
---------------------------------

In all participating hospitals, infection control nurses routinely review all hospitalizations for all types of HAIs (including bloodstream infection, pneumonia, surgical site infection, urinary tract infection, and other types of HAIs) using the US Centers for Disease Control and Prevention (CDC) (Atlanta, GA, USA) surveillance definitions [@pone.0071055-Garner1]. The identified HAI cases were notified to the TNIS. The reported data included the patient's age, gender, HAI onset date, site of infection, and microbiological results (e.g. organisms isolated from blood, urine, respiratory tract, surgical sites, and other non-sterile sites, as well as antimicrobial susceptibility). The onset date was the date when the first clinical symptom(s)/sign(s) occurred or the earliest positive culture was sampled, as specified for the type of HAI by the CDC definition.

Patients with *S. aureus* HAIs {#s2e}
------------------------------

We included all notified *S. aureus* HAIs cases that occurred at least 48 hours after admission in 2006--2008 for linkage with the NHI dataset. The flowchart is shown in [Figure 1](#pone-0071055-g001){ref-type="fig"}. If a patient had multiple episodes of HAIs during hospitalization, only the first episode and its first isolate were considered in this study. Cases with the HAI occurring within 48 hours of the admission or beyond the hospitalization period were excluded, because we used the length of stay before onset of the *S. aureus* HAI as one of the matching variables to identify a suitable matched uninfected inpatient [@pone.0071055-Cosgrove1], [@pone.0071055-Whitby1].

![Flowchart of patient selection for matching.](pone.0071055.g001){#pone-0071055-g001}

Matched Inpatients without HAIs {#s2f}
-------------------------------

Each *S. aureus* HAI case was individually matched at a 1∶2 ratio to inpatients without HAIs that were hospitalized during the same study period. The matching was based on age (within a 5-year difference), gender, as well as the same hospital, primary specialty/subspecialty, and indicators of underlying disease severity--including the length of stay before onset of the *S. aureus* HAI [@pone.0071055-Cosgrove1], [@pone.0071055-Whitby1] and the presence and type of seven classes of severe illnesses at admission (i.e. cancer, dialysis-dependent end stage renal disease, liver cirrhosis with complications, chronic ventilator dependence, major trauma, generalized autoimmune syndrome, and spinal injury/myeleterosis). If there were more than two candidate uninfected inpatients, we chose the two that had the closest admission dates to that of the *S. aureus* HAI case. If no suitable match was found, we reduced the matching requirement of primary specialty/subspecialty to just primary specialty. If a suitable match still could not be identified, we considered the matching process to have failed.

We used the NHI database to obtain patient data for individual matching and validation of comparability. The NHI in Taiwan has a coverage rate of 99% due to universal health insurance [@pone.0071055-Bureau1]. The NHI claims data recorded five major diagnoses (i.e. one primary diagnosis and up to four secondary diagnoses) for the patient, which were reported by the hospital based on the ICD--9--CM coding system. We ascertained the presence and type of severe illnesses using the Catastrophic Illness Registry, which is a subset of the NHI database (and thus has the same coverage rate). There are 30 major categories of catastrophic illnesses for which patient copayment can be exempted. The certification, which is strictly regulated by the NHI bureau, requires independent evaluation by two specialist physicians to confirm both the diagnosis and irreversibility of the illness [@pone.0071055-Bureau2].

Validation of Comparability {#s2g}
---------------------------

To validate comparability between the *S. aureus* HAI cases and matched uninfected inpatients on baseline characteristics before onset of *S. aureus* HAIs, we examined the between-group difference on clinical variables unrelated to HAIs (i.e. the presence of ischemic heart disease, congestive heart failure, stroke, diabetes, hypertension, elective surgical procedures, and medications for treating cardiovascular and/or neoplastic disorders).

Ascertainment of Outcomes {#s2h}
-------------------------

We derived the data on survival status and date of death using the National Death Registry (from Department of Health, Taiwan), which contains all the death certificates of Taiwanese citizens. The data on new-onset chronic ventilator dependence and dialysis-dependent end-stage renal disease were ascertained using the Catastrophic Illness Registry. To ensure a 100% one-year follow-up rate, data of both registries were updated to the end of year 2009. We used the date of Catastrophic Illness Certificate application as the onset date of chronic ventilator dependence and dialysis-dependent end-stage renal disease. To distinguish old events that were already present at admission from new-onset events that occurred after the index date, we defined the index date for *S. aureus* HAI patients as the onset date of the *S. aureus* HAI; that for uninfected patients was the admission date plus the length of stay before onset of the *S. aureus* HAI of the matched case. We used three linkage variables (encrypted personal ID, encrypted hospital ID, and admission date) to link the anonymized patient data between different datasets.

The data of hospital costs were obtained from the NHI dataset, which recorded the total cost (including diagnosis, laboratory, drug, ward, therapeutic-procedure, and special-material fees) for the entire hospitalization period of each patient.

Statistical Analysis {#s2i}
--------------------

We compared the main outcomes between the *S. aureus* HAI group and the uninfected group using multivariate conditional logistic regression stratified by matched pairs, with adjustment for the effects of diabetes mellitus and hypertension. We compared the length of hospital stay and the hospital cost between two groups using the random effect model. All statistical analyses were performed using SAS, version 9.2 (SAS Institute Inc., Cary, NC, USA). Statistical significance of P values was interpreted with Bonferroni's correction for multiple comparisons.

Results {#s3}
=======

The 114 hospitals reported a total of 47729 HAI cases during 2006--2008. Linking between the TNIS and the NHI dataset failed for 6587 cases (13.8%) due to inconsistency in one or more of the three linkage variables. Among the remaining 41142 HAI cases, the isolated pathogen was *S. aureus* for 4027 cases. Of them, 3563 cases met the inclusion criteria and 3070 cases were successfully matched to 6140 inpatients without HAIs (successful matching rate 86.2% \[3070/3563\]) ([Figure 1](#pone-0071055-g001){ref-type="fig"}). Compared to *S. aureus* HAI cases with successful matching, the *S. aureus* HAI cases with unsuccessful matching (n = 493) had a longer average length of stay before onset of the *S. aureus* HAI (95 vs. 20 days) and were more likely to have a severe illness at admission (14.0% vs. 3.7% for dialysis-dependent end-stage renal disease; 21.1% vs. 2.0% for chronic ventilator dependence) (all *P*s \<0.001).

Of the 3070 *S. aureus* HAI cases, the causal *S. aureus* strains were MRSA in 2201 cases (71.7%). Patients with MRSA HAIs tended to be older (mean age: 68 vs. 62 years), had a longer average length of stay before onset of the HAI (23 vs. 13 days), and were more likely to have a severe illness at admission (4.0% vs. 2.9% for dialysis-dependent end-stage renal disease; 2.5% vs. 0.6% for chronic ventilator dependence), compared with patients with MSSA HAIs (all *P*s \<0.001).

The baseline characteristics of the 3070 matched pairs are shown in [Table 1](#pone-0071055-t001){ref-type="table"}. There was no statistically significant between-group difference in the matching variables and the comparability-validation variables, with the only exceptions of diabetes mellitus and hypertension. Compared with the *S. aureus* HAI group, the uninfected group had a slightly higher proportion of patients with diabetes mellitus (22.1% vs. 19.4%, *P*\<0.001) and hypertension (23.2% vs. 16.8%, *P*\<0.001), as well as a lower average number of diagnoses recorded in the NHI dataset (4.3 vs. 4.7, *P*\<0.001).

10.1371/journal.pone.0071055.t001

###### Baseline characteristics of 3070 matched pairs.

![](pone.0071055.t001){#pone-0071055-t001-1}

                                                               *S. aureus* HAI Patients (n = 3070)   Matched Patients without HAIs (n = 6140)                  *P* value
  ----------------------------------------------------------- ------------------------------------- ------------------------------------------ -----------------------------------------
  **Matching Variables**                                                                                                                       
  Age, mean±SD/median (IQR)                                             67±19/72 (56--80)                       67±19/72 (56--80)                                 --
  Gender, female (%)                                                       1051 (34.2)                             2108 (34.2)                                    --
  Type of hospital, n (%)                                                                                                                      
   Medical center                                                          944 (30.8)                              1888 (30.8)                                    --
   Regional hospital                                                       1610 (52.4)                             3220 (52.4)                                    --
   Local hospital                                                          516 (16.8)                              1032 (16.8)                                    --
  Primary specialty,[\*](#nt102){ref-type="table-fn"} n (%)                                                                                    
   Neurosurgery                                                             259 (8.4)                               518 (8.4)                                     --
   Medicine                                                                 236 (7.7)                               472 (7.7)                                     --
   Surgery                                                                  170 (5.5)                               345 (5.6)                                     --
   Neurology                                                                136 (4.4)                               272 (4.4)                                     --
   Orthopedics                                                              116 (3.8)                               232 (3.8)                                     --
   Pediatrics                                                               70 (2.3)                                136 (2.2)                                     --
   Plastic Surgery                                                          61 (2.0)                                122 (2.0)                                     --
   Family Medicine                                                          48 (1.6)                                 96 (1.6)                                     --
  Severe illness, n (%)                                                                                                                        
   Cancer                                                                  520 (17.0)                              1040 (17.0)                                    --
   dialysis-dependent End-stage renal disease                               114 (3.7)                               228 (3.7)                                     --
   Liver cirrhosis with complications                                       60 (2.0)                                120 (2.0)                                     --
   Chronic ventilator dependence                                            60 (2.0)                                120 (2.0)                                     --
   Generalized autoimmune syndrome                                          32 (0.5)                                 16 (0.5)                                     --
   Spinal injury/myeleterosis                                                6 (0.2)                                 12 (0.2)                                     --
   Major trauma                                                             14 (0.5)                                 28 (0.5)                                     --
  **Validation Variables**                                                                                                                     
  Diagnosis, n (%)                                                                                                                             
   Ischemic heart disease                                                   217 (7.1)                               480 (7.8)                                    0.15
   Congestive heart failure                                                 226 (7.4)                               444 (7.2)                                    0.81
   Stroke                                                                  424 (13.8)                               848 (13.8)                                    1.0
   Diabetes mellitus                                                       594 (19.4)                              1354 (22.1)                   0.001[†](#nt103){ref-type="table-fn"}
   Hypertension                                                            516 (16.8)                              1427 (23.2)                  \<0.001[†](#nt103){ref-type="table-fn"}
  Procedure, n (%)                                                                                                                             
  Total joint replacement                                                   16 (0.5)                                 43 (0.7)                                    0.31
  Coronary artery bypass graft                                              33 (1.1)                                 43 (0.7)                                    0.06
  Rectoscopy                                                                11 (0.4)                                 13 (0.2)                                    0.19
  Laparoscopy                                                                6 (0.2)                                 14 (0.2)                                    0.52
  Medication, n (%)                                                                                                                            
  Statins                                                                   154 (5.0)                               310 (5.0)                                    0.95
   Streptokinase                                                            17 (0.6)                                 25 (0.4)                                    0.33
   Antigout preparations                                                    293 (9.5)                               506 (8.2)                                    0.04
   Antineoplastic agents                                                    159 (5.2)                               387 (6.3)                                    0.03

Abbreviations: HAI, healthcare-associated infection; SD, standard deviation; IQR, interquartile range.

Eight out of 15 primary specialties with the most patients were listed.

Statistically significant, after Bonferroni correction (*P*\<0.05/13 = 0.0038).

[Table 2](#pone-0071055-t002){ref-type="table"} summarizes the main outcomes. *S. aureus* HAI cases had an excess in-hospital mortality, mortality within 30 days after discharge, and one-year mortality of 19.9%, 21.1%, and 20.2%, respectively (all *P*s \<0.001) ([Table 2](#pone-0071055-t002){ref-type="table"}). The excess one-year mortality was highest for nosocomial pneumonia (28.5%) and bloodstream infection (22.3%) ([Table 3](#pone-0071055-t003){ref-type="table"}). MRSA and MSSA cases had an excess one-year mortality of 21.8% and 16.1%, respectively ([Table 3](#pone-0071055-t003){ref-type="table"} and [Figure 2](#pone-0071055-g002){ref-type="fig"}). *S. aureus* HAIs cases also had an excess risk for new-onset chronic ventilator dependence during hospitalization, within 30 days after discharge, and within one-year (6.8%, 7.6%, and 7.3%, respectively, all *P*s \<0.001). The excess risk for new-onset dialysis-dependent end-stage renal disease during hospitalization, within 30 days after discharge, and within one-year was 1.7%, 2.3%, and 2.6%, respectively (all *P*s \<0.001). After adjusting for the presence of diabetes mellitus and hypertension, the differences in outcomes between the *S. aureus* HAI group and the uninfected group remained highly statistically significant (all *P*s \<0.001) ([Table 2](#pone-0071055-t002){ref-type="table"}).

![Kaplan-Meier survival curves (A) MSSA patients (n = 869) and their matched uninfected patients (n = 1738).\
(B) MRSA patients (n = 2201) and their matched uninfected patients (n = 4402).](pone.0071055.g002){#pone-0071055-g002}

10.1371/journal.pone.0071055.t002

###### Excess risks for mortality and new-onset organ failure in patients with *S. aureus* HAIs.

![](pone.0071055.t002){#pone-0071055-t002-2}

  Outcomes                         Endpoint of Observation[\*](#nt105){ref-type="table-fn"}   *S. aureus* HAI Patients   Matched Patients without HAIs   Excess Risk(%)                   OR                    Adjusted OR[‡](#nt107){ref-type="table-fn"}
  ------------------------------- ---------------------------------------------------------- -------------------------- ------------------------------- ---------------- ------------------------------------- ---------------------------------------------
  Mortality                                            Number at risk\#                                 3070                         6140                      --                         --                                        --
                                                          Discharge                                  956 (31.1)                   691 (11.3)                  19.9        4.5[†](#nt108){ref-type="table-fn"}       4.3[†](#nt108){ref-type="table-fn"}
                                                    30-day after discharge                          1188 (38.7)                   1082 (17.6)                 21.1        3.8[†](#nt108){ref-type="table-fn"}       3.7[†](#nt108){ref-type="table-fn"}
                                                           one-year                                 1828 (59.5)                   2416 (39.3)                 20.2        3.2[†](#nt108){ref-type="table-fn"}       3.1[†](#nt108){ref-type="table-fn"}
  Chronic ventilator dependence                        Number at risk\#                                 3010                         6020                      --                         --                                        --
                                                          Discharge                                  279 (9.3)                     151 (2.5)                  6.8         4.8[†](#nt108){ref-type="table-fn"}       4.6[†](#nt108){ref-type="table-fn"}
                                                    30-day after discharge                           329 (10.9)                    203 (3.4)                  7.6         4.2[†](#nt108){ref-type="table-fn"}       4.1[†](#nt108){ref-type="table-fn"}
                                                           one-year                                  393 (13.1)                    349 (5.8)                  7.3         2.8[†](#nt108){ref-type="table-fn"}       2.7[†](#nt108){ref-type="table-fn"}
  Dialysis-dependent end-stage                         Number at risk\#                                 2956                         5912                      --                         --                                        --
  renal disease                                           Discharge                                   77 (2.6)                     53 (0.9)                   1.7         3.5[†](#nt108){ref-type="table-fn"}       4.1[†](#nt108){ref-type="table-fn"}
                                                    30-day after discharge                           120 (4.1)                     105 (1.8)                  2.3         2.9[†](#nt108){ref-type="table-fn"}       3.6[†](#nt108){ref-type="table-fn"}
                                                           one-year                                  153 (5.2)                     153 (2.6)                  2.6         2.6[†](#nt108){ref-type="table-fn"}       3.2[†](#nt108){ref-type="table-fn"}

Abbreviations: HAI, healthcare-associated infection; OR, odds ratio.

Follow-up duration from index date to endpoint of observation.

Number at risk: the number of patients who have not yet developed the outcomes at admission.

Adjusted for diabetes mellitus and hypertension.

Statistically significant, after Bonferroni correction (all *P*\<0.05/18 = 0.0028).

10.1371/journal.pone.0071055.t003

###### Subgroup analysis of excess one-year mortality.
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                                                                                                                  *S. aureus* HAI Patients   Matched Patients without HAIs   \% Difference    *P* value          
  -------------------------------------------------------------------------------------------------------------- -------------------------- ------------------------------- --------------- ------------- ------ -----------------------------------------
  one-year mortality, n (%)                                                                                                 3070                      1828 (59.5)                6140        2416 (39.3)   20.2   \<0.001[†](#nt111){ref-type="table-fn"}
  By site of infection of index *S. aureus* HAI cases                                                                                                                                                            
  Bloodstream infection                                                                                                     1329                      878 (66.1)                 2658        1162 (43.7)   22.3   \<0.001[†](#nt111){ref-type="table-fn"}
  Pneumonia                                                                                                                 785                       540 (68.8)                 1570        632 (40.3)    28.5   \<0.001[†](#nt111){ref-type="table-fn"}
  Urinary tract infection                                                                                                   206                       111 (53.9)                  412        186 (45.1)    8.7    \<0.001[†](#nt111){ref-type="table-fn"}
  Surgical site infection                                                                                                   310                       102 (32.9)                  620        127 (20.5)    12.4   \<0.001[†](#nt111){ref-type="table-fn"}
  Others                                                                                                                    440                       197 (44.8)                  880        309 (35.1)    9.7    \<0.001[†](#nt111){ref-type="table-fn"}
  By antimicrobial resistance of index *S. aureus* HAI cases                                                                                                                                                     
  MSSA                                                                                                                      869                       419 (48.2)                 1738        558 (32.1)    16.1   \<0.001[†](#nt111){ref-type="table-fn"}
  MRSA                                                                                                                      2201                      1409 (64.0)                4402        1858 (42.2)   21.8   \<0.001[†](#nt111){ref-type="table-fn"}
  By presence of severe illnesses[\*](#nt110){ref-type="table-fn"} at admission of index *S. aureus* HAI cases                                                                                                   
  No                                                                                                                        2295                      1255 (54.7)                4590        1491 (32.5)   22.2   \<0.001[†](#nt111){ref-type="table-fn"}
  Yes                                                                                                                       775                       573 (73.9)                 1550        925 (59.7)    14.2   \<0.001[†](#nt111){ref-type="table-fn"}

Abbreviations: HAI, healthcare-associated infection; SD, standard deviation; MSSA, methicillin-susceptible *S. aureus*; MRSA, methicillin- resistant *S. aureus*.

Any of the 7 classes of severe illnesses (cancer, dialysis-dependent end stage renal disease, liver cirrhosis with complications, chronic ventilator dependence, generalized autoimmune syndrome, spinal injury/myeleterosis, and major trauma).

Statistically significant, after Bonferroni correction (*P*\<0.05/10 = 0.005).

Patients with *S. aureus* HAIs had an excess hospital stay of 12 days and an extra hospital cost of \$5978 compared with the matched uninfected patients ([Table 4](#pone-0071055-t004){ref-type="table"}). The differences were significant in subgroup analysis by the site of infection (bloodstream, pneumonia, urinary tract, and surgical site of infection), the type of antimicrobial resistance (MSSA and MRSA), and the presence (or absence) of severe illnesses at admission (all *P*s \<0.001) ([Table 4](#pone-0071055-t004){ref-type="table"}).

10.1371/journal.pone.0071055.t004

###### Subgroup analysis of excess hospital stay and costs.
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                                                                                                                 *S. aureus* HAI Patients   Matched Patients without HAIs   Mean Difference    *P* value           
  ------------------------------------------------------------------------------------------------------------- -------------------------- ------------------------------- ----------------- -------------- ------ -----------------------------------------
  Length of stay, mean (SD), days                                                                                          3070                        45 (51)                   6140           33 (50)       12    \<0.001[†](#nt115){ref-type="table-fn"}
  By site of infection of index *S. aureus* HAI cases                                                                                                                                                              
  Bloodstream infection                                                                                                    1329                        42 (35)                   2658           33 (43)       9     \<0.001[†](#nt115){ref-type="table-fn"}
  Pneumonia                                                                                                                785                         47 (54)                   1570           30 (48)       17    \<0.001[†](#nt115){ref-type="table-fn"}
  Urinary tract infection                                                                                                  206                         51 (64)                    412           46 (63)       5     \<0.001[†](#nt115){ref-type="table-fn"}
  Surgical site infection                                                                                                  310                         44 (36)                    620           28 (28)       16    \<0.001[†](#nt115){ref-type="table-fn"}
  Others                                                                                                                   440                         50 (79)                    880           38 (73)       12    \<0.001[†](#nt115){ref-type="table-fn"}
  By antimicrobial resistance of index *S. aureus* HAI cases                                                                                                                                                       
  MSSA                                                                                                                     869                         34 (40)                   1738           23 (36)       11    \<0.001[†](#nt115){ref-type="table-fn"}
  MRSA                                                                                                                     2201                        50 (54)                   4402           37 (54)       13    \<0.001[†](#nt115){ref-type="table-fn"}
  By presence of severe illnesses[\*](#nt113){ref-type="table-fn"} at admission of index*S. aureus* HAI cases                                                                                                      
  No                                                                                                                       2295                        46 (53)                   4590           33 (49)       13    \<0.001[†](#nt115){ref-type="table-fn"}
  Yes                                                                                                                      775                         42 (45)                   1550           35 (54)       7     \<0.001[†](#nt115){ref-type="table-fn"}
  Cost of hospitalization, mean (SD), in US dollars [‡](#nt114){ref-type="table-fn"}                                       3070                     12879 (13043)                6140         6900 (9006)    5979   \<0.001[†](#nt115){ref-type="table-fn"}
  By site of infection of index *S. aureus* HAI cases                                                                                                                                                              
  Bloodstream infection                                                                                                    1329                     12441 (12822)                2658         7085 (9357)    5355   \<0.001[†](#nt115){ref-type="table-fn"}
  Pneumonia                                                                                                                785                      14657 (13431)                1570         6285 (8374)    8373   \<0.001[†](#nt115){ref-type="table-fn"}
  Urinary tract infection                                                                                                  206                      11468 (12448)                 412         8477 (10351)   2991   \<0.001[†](#nt115){ref-type="table-fn"}
  Surgical site infection                                                                                                  310                      12922 (13114)                 620         6488 (6680)    6435   \<0.001[†](#nt115){ref-type="table-fn"}
  Others                                                                                                                   440                      11658 (12946)                 880         6991 (9645)    4667   \<0.001[†](#nt115){ref-type="table-fn"}
  By antimicrobial resistance of index *S. aureus* HAI cases                                                                                                                                                       
  MSSA                                                                                                                     869                       8280 (8869)                 1738         4378 (5520)    3903   \<0.001[†](#nt115){ref-type="table-fn"}
  MRSA                                                                                                                     2201                     14694 (13951)                4402         7896 (9880)    6798   \<0.001[†](#nt115){ref-type="table-fn"}
  By presence of severe illnesses[\*](#nt113){ref-type="table-fn"} at admission of index*S. aureus* HAI cases                                                                                                      
  No                                                                                                                       2295                     13437 (13571)                4590         6852 (8826)    6585   \<0.001[†](#nt115){ref-type="table-fn"}
  Yes                                                                                                                      775                      11225 (11181)                1550         7041 (9520)    4183   \<0.001[†](#nt115){ref-type="table-fn"}

Abbreviations: HAI, healthcare-associated infection; SD, standard deviation; MSSA, methicillin-susceptible *S. aureus*; MRSA, methicillin- resistant *S. aureus*.

Any of the 7 classes of severe illnesses (cancer, dialysis-dependent end stage renal disease, liver cirrhosis with complications, chronic ventilator dependence, generalized autoimmune syndrome, spinal injury/myeleterosis, and major trauma).

At an exchange rate of 30 New Taiwan Dollars (NT\$s)/US\$.

Statistically significant, after Bonferroni correction (*P*\<0.05/20 = 0.0025).

Discussion {#s4}
==========

This study is the largest cohort study to date that has investigated the negative effects of *S. aureus* HAIs on the outcomes of hospitalized patients. Using national databases, we included 3070 inpatients with *S. aureus* HAIs and 6140 matched uninfected inpatients. Our results show that *S. aureus* HAIs significantly increased the risks for long-term mortality and disabilities including new-onset chronic ventilator dependence and new-onset dialysis-dependent end-stage renal disease, with an excess one-year risk of 20.2%, 7.3%, and 2.6%, respectively (all *P*s\<0.001). *S. aureus* HAIs were also associated with an excess hospital stay of 12 days and an extra hospital cost of \$5978 (*P*s\<0.001).

In addition to a large sample size, our study has the advantage of enhancing comparability by individually matching the *S. aureus* HAI cases to uninfected inpatients on potential confounding factors including age, gender, hospital, primary specialty/subspecialty, and underlying disease severity. Analysis of the validation variables did show a lack of difference in most baseline characteristics (e.g. the frequency of cardiovascular diseases, elective surgery, and antineoplastic agent use), with the exception of a slightly higher proportion of patients with diabetes mellitus and hypertension in the uninfected group. The most likely explanation for the difference is that diabetes mellitus and hypertension were more likely to be recorded among the five major diagnoses of the patient in the NHI database for the uninfected group that had a lower average number of diagnoses. Even if the result reflects a genuine difference in these two comorbidities, the higher proportions of patients with diabetes mellitus and hypertension (which may adversely affect the outcomes) in the uninfected group would have caused an underestimation for the negative impact of *S. aureus* HAIs and thus the actual excess risks would have been higher than the observed values.

Our findings on the excess mortality, prolonged hospital stay, and extra hospital costs associated with *S. aureus* HAIs are consistent with the existing literature [@pone.0071055-Anderson1]--[@pone.0071055-Chaix1]. Previous studies, which involved smaller numbers of patients and mainly focused on surgical site infections, reported an excess 90-day crude mortality of 10.5--16.8% for patients with *S. aureus* surgical site infections [@pone.0071055-Anderson1], [@pone.0071055-McGarry1], [@pone.0071055-Engemann1]. Using population-based data, our study validates the previous results and found an excess one-year mortality of 12.4%. Furthermore, our study extends the results to patients with *S. aureus* HAIs in general. We also first show that patients with *S. aureus* pneumonia and bloodstream infection suffered the highest excess one-year mortality of 28.5% and 21.3%, respectively.

In addition to an excess infection-related mortality, our study shows that *S. aureus* HAIs increase the risk for long-term disability. Severe *S. aureus* infections can cause acute organ dysfunction [@pone.0071055-Martin1], particularly in patients with pre-existing chronic lung or renal disease(s). Blot et al. compared 85 cases of *S. aureus* bacteremia with 170 matched uninfected patients and found that the former had a significantly longer length of ventilator dependence than the latter [@pone.0071055-Burton1]. Reach et al. composed a large study of 1575 matched pairs and found that MRSA patients were more likely to undergo mechanical ventilation than uninfected patients (excess risk: 7.5%) [@pone.0071055-Resch1]. Our study first provides evidence on the potential irreversibility of *S. aureus* HAIs-related ventilator dependence and renal failure, showing that *S. aureus* HAIs increased the risks for new-onset chronic ventilator dependence and dialysis-dependent end-stage renal disease by 7.3% and 2.6%, respectively, compared with patients with the same type and severity of underlying disease but without HAIs. Therefore, *S. aureus* HAIs can cause irreversible organ dysfunction and profoundly affect the patient's long-term well-being.

The excess risks for long-term mortality and disability highlight the importance to reduce occurrence of *S. aureus* HAI, which is a preventable disease. One of the main causes for the spread of MRSA within hospitals is poor hand hygiene compliance among healthcare workers [@pone.0071055-Burke1]. Studies have found that the incidence of HAIs can be decreased by the introduction of hand hygiene programs and other measures [@pone.0071055-Sroka1]. There is growing literature supporting the beneficial effects of hand hygiene [@pone.0071055-Tseng1], [@pone.0071055-Chen2]. A systemic review of 30 intervention studies suggested that 10--70% of HAIs are probably preventable with appropriate infection control [@pone.0071055-Harbarth1]. A recent randomized controlled trial proves that active surveillance and decolonization of nasal *S. aureus* carriers on admission can further reduce the incidence rate of surgical site infection [@pone.0071055-Bode1].

Our results on the excess mortality/disability and excess hospital stay/costs indicate that a reduction in incidence of *S. aureus* HAIs can translate to improved long-term outcomes and significant cost savings, particularly when the huge financial burdens of providing long-term ventilator and dialysis services are taken into consideration.

Our study was limited by the voluntary nature of TNIS participation and HAI case notification. The 114 hospitals in current study may not represent all hospitals in Taiwan. Nevertheless, we minimize the potential effect of self-selection bias on the estimated excess risk associated with *S. aureus* HAIs, by individually matching the *S. aureus* HAI cases to uninfected inpatients by the hospital. Because the notification of HAI cases was also voluntary, it is possible that some of the 6140 matched uninfected inpatients might indeed have HAIs, which would have caused an underestimation of *S. aureus* HAI-associated excess risks for long-term mortality and disability. Therefore, our findings represent a conservative estimate for the negative impact of *S. aureus* HAIs.

Conclusion {#s4a}
----------

*S. aureus* HAIs have substantial negative effect on the long-term outcome of hospitalized patients in terms of both mortality and disability, which should be taken into consideration in future cost-effectiveness studies of the control and prevention interventions for *S. aureus* HAIs.
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